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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Norwegian 
language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic and clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 301 JIA patients (3.3% systemic, 41.2% oligoarticular, 25.9% RF negative 
polyarthritis, and 29.6% other categories) and 74 healthy children were enrolled in three centres. The JAMAR components 
discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. 
In conclusion, the Norwegian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable 
for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Norwegian parent, child/adult version of 
the Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Norwegian language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6], and enrolled from March 2012 to 
September 2013. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do, and not applicable if it was not possible to answer 
the question or the child was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW), and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic and clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal item-scale correla-
tions (Pearson r: all items within a scale should contrib-
ute equally to the total score); the third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
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Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with first and 
third quartiles and categorical data as absolute frequencies 
and percentages.
The complete Norwegian parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Norwegian JAMAR was fully cross-culturally adapted 
from the standard English version with two forward and two 
backward translations with a concordance for 112/123 trans-
lations lines (91.1%) for the parent version and 109/120 lines 
(90.8%) for the child version.
Of the 123 lines in the parent version of the JAMAR, 
116 (94.3%) lines were understood by at least 80% of the 10 
parents tested (median = 100%; range: 50–100%); 107/120 
(89.1%) lines in the patient version of the JAMAR were 
understood by at least 80% of the children (median = 100%; 
range: 20–100%). Lines 1, 6, 66, 73, 97, 114, and 118 of the 
parent version of the JAMAR were modified considering 
parents’ suggestions. Lines 1, 23, 62, 64, 76, 77, 78, 79, 80, 
94, 114, 116, and 119 of the patient version of the JAMAR 
were modified considering patients suggestions.
Demographic and clinical characteristics 
of the subjects
A total of 301 JIA patients and 74 healthy children (total of 
375 subjects) were enrolled at three paediatric rheumatol-
ogy centres.
In the 301 JIA subjects, the JIA categories were 3.3% 
with systemic arthritis, 41.2% with oligoarthritis, 25.9% 
with RF negative polyarthritis, 3.3% with RF positive pol-
yarthritis, 4.0% with psoriatic arthritis, 9.0% with enthesitis-
related arthritis, and 13.3% with undifferentiated arthritis 
(Table 1).
A total of 357/375 (95.2%) subjects had the parent ver-
sion of the JAMAR completed by a parent (285 from parents 
of JIA patients and 72 from parents of healthy children). The 
JAMAR was completed by 289/357 (81.0%) mothers and 
68/357 (19.0%) fathers. The child version of the JAMAR 
was completed by 298/375 (79.5%) children age 6.5 or older. 
In addition, patients younger than 7 years old, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (first–third quartiles)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had a 
greater level of disability and pain, as well as a lower overall 
well-being and HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all the JAMAR items, the median number of missing 
responses was 0.4 (0.4–0.4).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items, whereas a reduced number of response 
choices were used for PF items 9, 11, 14 and 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 1% (1–2%) for the PF and 8% (6–9%) for 
the HRQoL.
Floor and ceiling effect
The median floor effect was 83.5% (75.4–92.3%) for the PF 
items, 52.6% (38.6–59.3%) for the HRQoL PhH items, and 
58.2% (54.4–68.4%) for the HRQoL PsH items. The median 
ceiling effect was 0.4% (0–0.7%) for the PF items, 2.8% 
(2.1–7.4%) for the HRQoL PhH items, and 1.4% (1.1–1.4%) 
for the HRQoL PsH items. The median floor effect was 
26.7% for the pain VAS, 22.8% for the disease activity VAS, 
and 27.7% for the well-being VAS. The median ceiling effect 
was 0.3% for the pain VAS, 0.7% for the disease activity 
VAS, and 0.3% for the well-being VAS.
Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies, and %) for the 301 JIA patients
Data related to the JAMAR refer to the 285 JIA patients and to the 72 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, # p < 0.0001
Systemic Oligoarthritis RF− polyar-
thritis
RF+ polyar-
thritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 10 N = 124 N = 78 N = 10 N = 12 N = 27 N = 40 N = 301 N = 74
Female 7 (70%) 96 (77.4%) 53 (67.9%) 8 (80%) 7 (58.3%) 10 (37%) 28 (70%) 209 (69.4%)* 35 (47.3%)**
Age at visit 12.6 (8–16.1) 11.2 
(7.1–14.2)
11.5 
(8.7–15.4)
15.4 (11.6–
16.6)
12.7 (11.4–
16.2)
15.2 (12.4–
17.2)
14.7 (10.5–
16.3)
12 (8.3–
15.4)**
12.9 (9.8–15.9)
Age at onset 4 (1.9–6.6) 2.8 (1.8–5.7) 2.5 (1.6–8.3) 10.4 
(5.1–14.2)
8.6 (5.2–11.4) 8.7 (6.2–
11.9)
6.4 (2.2–
11.3)
3.7 (1.9–8.8)#
Disease duration 9.3 (1.7–
12.5)
6 (2.3–9.2) 5.9 (3.2–9.7) 2.2 (1.2–7.3) 3.9 (1.6–7.3) 4.9 (3.7–8.4) 5 (2.4–9) 5.8 (2.5–9)
ESR 6 (2–12) 7 (4–12) 7 (3–11) 6 (2–12) 6 (3–8) 6 (4–10) 7.5 (5–12) 7 (4–12)
MD VAS 1 (0–2) 1 (0–2) 1 (0–2) 1.5 (0.5–3) 2.5 (2–3) 0 (0–1) 1 (0–2) 1 (0–2)
No. swollen joints 0 (0–0) 0 (0–1) 0 (0–1) 1 (0–8) 1 (0–1.5) 0 (0–0) 0 (0–1) 0 (0–1)*
No. joints with 
pain
0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 1.5 (0–2) 0 (0–1) 0 (0–1) 0 (0–1)
No. joints with 
LOM
0 (0–2) 0 (0–1) 0 (0–2) 0 (0–2) 1 (0–4.5) 0 (0–1) 0 (0–1) 0 (0–1)
No. active joints 0 (0–1) 0 (0–1) 0 (0–1) 1 (0–8) 1.5 (0–2.5) 0 (0–1) 0 (0–1) 0 (0–1)
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ANA status 0 (0%) 27 (21.8%) 17 (21.8%) 3 (30%) 2 (16.7%) 2 (7.4%) 7 (17.5%) 58 (19.3%)
Uveitis 1 (10%) 32/123 (26%) 18 (23.1%) 1 (10%) 2 (16.7%) 7 (25.9%) 15/39 
(38.5%)
76/299 
(25.4%)
PF total score 2.5 (0–4) 1 (0–3) 2 (0–6) 1 (0–1) 4 (0–20) 0 (0–3.5) 1 (0–4) 1 (0–4) 0 (0–0)#
Pain VAS 1.5 (0–2.5) 1.5 (0–3.5) 1.5 (0.5–4.5) 2 (0.5–2.5) 4.5 (4–7) 1 (0–4) 1.5 (0–4) 2 (0–4)* 0 (0–0) #
Disease activity 
VAS
2.3 (0–5) 1.5 (0.5–3.5) 2 (0.5–5) 1 (0–3.5) 4 (2.5–7) 1.3 (0–3.3) 1.5 (0.5–4) 2 (0.5–4)
Well-being VAS 1.3 (0–2) 1 (0–3) 2 (0.5–3) 1 (0–3) 4.5 (1–7) 0.8 (0–2.5) 1 (0–3.5) 1 (0–3)
HRQoL PhH 3.5 (2–6) 3 (1–5) 3 (1–6) 3 (1–3) 7 (3–10) 1 (0–6) 3 (1–5) 3 (1–5)* 0 (0–1)#
HRQoL PsH 2 (1–3) 2 (0–4) 2 (0–4) 1 (0–2) 2 (1–4) 1 (0–3) 1 (0–3) 2 (0–4) 0 (0–1)#
HRQoL Total 
Score
5 (4–10) 5 (1–9) 5 (2–10) 4 (1–6) 9 (5–16) 2.5 (0.5–9.5) 5 (2–7) 5 (2–9) 0 (0–1)#
Pain/swell. in > 1 
joint
4 (40%) 88/123 
(71.5%)
48/74 (64.9%) 6/9 (66.7%) 10/11 (90.9%) 11/24 
(45.8%)
22/34 
(64.7%)
189/285 
(66.3%)
6/72 (8.3%)#
Morning stiff-
ness > 15 min
2 (20%) 41/122 
(33.6%)
35/73 (47.9%) 3/9 (33.3%) 8/11 (72.7%) 7/24 (29.2%) 13/34 
(38.2%)
109/283 
(38.5%)
1/72 (1.4%)#
Subjective remis-
sion
4 (40%) 79/123 
(64.2%)
46/73 (63%) 6/9 (66.7%) 10/11 (90.9%) 13/24 
(54.2%)
21/34 
(61.8%)
179/284 
(63%)
In treatment 9 (90%) 84/123 
(68.3%)
63/73 (86.3%) 9/9 (100%) 11/11 (100%) 21/24 
(87.5%)
28/34 
(82.4%)
225/284 
(79.2%)*
Reporting side 
effects
5/9 (55.6%) 39/84 
(46.4%)
33/63 (52.4%) 1/9 (11.1%) 8/11 (72.7%) 9/21 (42.9%) 15/28 
(53.6%)
110/225 
(48.9%)
Taking medica-
tion regularly
9/9 (100%) 76/84 
(90.5%)
57/63 (90.5%) 7/9 (77.8%) 11/11 (100%) 20/21 
(95.2%)
25/28 
(89.3%)
205/225 
(91.1%)
With problems 
attending school
1/4 (25%) 20/74 (27%) 18/45 (40%) 0 (0%) 5/7 (71.4%) 5/19 (26.3%) 5/19 (26.3%) 54/172 
(31.4%)
0 (0%)#
Satisfied with dis-
ease outcome
9 (90%) 85/123 
(69.1%)
44/73 (60.3%) 6/9 (66.7%) 4/11 (36.4%) 16/24 
(66.7%)
28/34 
(82.4%)
192/284 
(67.6%)
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items, with the exception of PF items 11 and 15, and for 90% 
of the HRQoL items, with the exception of item 1.
Item internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 11 and 15) and 100% of items 
of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
a Frequency of items at lower and higher extremes of the scale, respectively
Parent N = 285/357 Child N = 228/298
Missing values (1st–3rd quartiles) 0.4 (0.4–0.4) 0.9 (0.4–0.9)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect,  mediana
 PF 83.5% 81.1%
 HRQoL PhH 52.6% 53.9%
 HRQoL PsH 58.2% 59.6%
 Pain VAS 26.7% 25.9%
 Disease activity VAS 22.8% 26.3%
 Well-being VAS 27.7% 35.5%
Ceiling effect,  mediana
 PF 0.4% 0.4%
 HRQoL PhH 2.8% 2.2%
 HRQoL PsH 1.4% 1.8%
 Pain VAS 0.3% 0.4%
 Disease activity VAS 0.7% 0.0%
 Well-being VAS 0.3% 1.3%
Items with equivalent item-scale correlation 87% for PF, 90% for HRQoL 73% for PF, 90% for HRQoL
Items with item-scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 87% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.86 0.86
 PF-HW 0.85 0.80
 PF-US 0.69 0.74
 HRQoL PhH 0.87 0.86
 HRQoL PsH 0.83 0.83
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.66 0.63
 HRQoL PhH 0.72 0.80
 HRQoL PsH 0.55 0.70
Spearman correlation with JIA core-set variables, median
 PF 0.5 0.4
 HRQoL PhH 0.5 0.4
 HRQoL PsH 0.3 0.3
 Pain VAS 0.3 0.3
 Disease activity VAS 0.2 0.3
 Well-being VAS 0.4 0.4
S296 Rheumatology International (2018) 38 (Suppl 1):S291–S298
1 3
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.86 for PF-LL, 0.85 for PF-HW, and 
0.69 for PF-US. Cronbach’s alpha was 0.87 for HRQoL PhH 
and 0.83 for HRQoL PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 9 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 7 days (7–17 days). The intraclass correlation 
coefficients (ICC) for the PF total score showed a substan-
tial reproducibility (ICC = 0.66). The ICC for the HRQoL 
PhH showed a substantial reproducibility (ICC = 0.72), 
while the ICC for the HRQoL PsH showed a moderate 
reproducibility (ICC = 0.55).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.3 to 0.6 
(median = 0.5). The PF total score best correlation was 
observed with the parent disease activity VAS (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.2 to 0.7 (median = 0.5), whereas that for the PsH 
ranged from 0.1 to 0.6 (median = 0.3). The PhH showed 
the best correlation with the parent’s assessment of pain 
(r = 0.8, p < 0.001) and the PsH with the parent global 
assessment of well-being (r = 0.6, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, 
and the parent disease activity VAS and the physician-
centred and laboratory measures were 0.3 (0.2–0.5), 0.2 
(0.2–0.4), and 0.4 (0.3–0.6), respectively.
Discussion
In this study, the Norwegian version of the JAMAR was 
cross-culturally adapted from the original standard Eng-
lish version with two forward and two backward transla-
tions. According to the results of the validation analysis, 
the Norwegian parent and patient versions of the JAMAR 
show satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated 
well between patients with JIA and healthy controls. The 
HRQoL psychosocial health score proved to discriminate 
between the different JIA subtypes with children with pso-
riatic arthritis having a lower quality of life, which is in 
line with other recent studies [19].
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: two PF items (stretch 
arms and bite a sandwich or an apple) showed a lower 
item’s internal consistency. However, the overall internal 
consistency was good for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core-set 
parameters ranged from weak to strong.
The results obtained for the parent version of the 
JAMAR are very similar to those obtained for the child 
version, which demonstrates that children are equally reli-
able proxy reporters of their disease and health status as 
their parents. The JAMAR is aimed to evaluate the side 
effects of medications and school attendance, which are 
other dimensions of daily life that were not previously con-
sidered by other HRQoL tools. This may provide useful 
information for intervention and follow-up in health care.
In conclusion, the Norwegian version of the JAMAR 
was found to have satisfactory psychometric properties, 
and it is, thus, a reliable and valid tool for the multidimen-
sional assessment of children with JIA.
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